Moderna shares plunge after cutting research budget
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
Go back to Moderna shares plunge after cutting research budget
September 12, 2024 6:02 AM EDT
Focuses on ten product approvals through 2027
Expects to submit next-generation COVID vaccine for approval in 2024
Expects to submit flu/COVID combination vaccine for approval in 2024
Announces positive Phase 3 results for its RSV vaccine for high-risk adults aged 18 to 59; expects to submit sBLA for U.S. approval in 2024
Announces positive Phase 3 results for its standalone flu vaccine for adults aged 65 and older relative to high-dose licensed comparator
Announces norovirus vaccine advances into Phase 3 study, bringing the total of non-respiratory pivotal... More
September 10, 2024 7:30 AM EDT
Building on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases
Moderna nominated two autoimmune disease targets under the collaboration
Carisma is eligible to receive milestones and royalty payments
PHILADELPHIA, Sept. 10, 2024 /PRNewswire/ --Â ... More
